Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on September 8, 2026. The filing reports corporate governance changes effective as of the report date, specifically the expansion of the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The only financial disclosure relates to director compensation:
- Director Retainer: $50,000 annual cash retainer per new director, payable quarterly.
- Equity Grant: Option to purchase 100,000 shares of common stock per new director.
- Vesting Schedule: 36 equal monthly installments beginning one month after the grant date.
Material Changes
The Board of Directors increased the number of directors to seven and appointed two new independent directors:
- R. Duane Clark II: Appointed as Director and member of the Nominating and Corporate Governance Committee. He brings over 40 years of experience in pharmaceuticals and biotechnology, currently serving as General Manager, U.S. Rare Diseases at Sanofi.
- James Sapirstein: Appointed as Director and member of the Nominating and Corporate Governance Committee. He brings over 40 years of biopharmaceutical leadership, currently serving as CEO of Cocrystal Pharma, Inc. and 8 Prime Biosciences.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. The appointments are intended to leverage the new directors' expertise in rare diseases, immunology, commercialization, and capital formation.
Key Facts for Investor Verification
- Verify the total number of directors on the Board is now seven.
- Confirm the vesting terms of the 100,000 share options granted to Messrs. Clark and Sapirstein.
- Review the press release dated September 14, 2026 (Exhibit 99.1) for additional context on the appointments.
- Note that this filing does not provide updated financial performance metrics for the company.